VTVT

vTv Therapeutics Inc.
CAPPED RATING

vTv Therapeutics Inc is a biopharmaceutical company engaged in drug discovery and development. Its therapies are intended to treat diseases such as Alzheimer\'s and type-II diabetes. Its other products include TTP399, type II diabetes drug candidate.

vTv Therapeutics Inc. (VTVT) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Growth (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
F
Factor Score 0.1 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.1
EV / EBITDA -15.3
Rev Growth YoY N/A
Gross Margin 20.8%
Price Return 3M -37.1%
Price Return 12M -36.5%
Catalyst Signal 0.00
Market Cap $79.0M
TTM Revenue $36.8M
Price / Sales 2.1
ROE -11.0%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) F (0.1) B- (3.1) C- (2.0) C+ (2.6) C (2.2)
2026-11-08 B- (3.0) D- (1.0) B- (3.1) C (2.4) C+ (2.6) C (2.4)
2026-11-01 B- (3.0) F (0.2) B- (3.1) C+ (2.8) C+ (2.7) C (2.4)
2026-10-25 B- (3.0) F (0.2) B (3.2) C+ (2.5) C+ (2.6) C (2.3)
2026-10-18 B- (3.0) F (0.1) B (3.2) C (2.3) C+ (2.6) C (2.3)
Page 1 of 6